Product Information
CEVIMELINE HCL 30 MG CAPSULE is a generic product labeled by Hikma Pharmaceuticals USA Inc., priced at $0.7289 per EA under NDC 00054033425. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on Jul 8, 2013. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
30 mg/1
Manufacturer
Hikma Pharmaceuticals USA Inc.NDC
00054033425
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
CEVIMELINE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA091591FDA Approved
7/8/2013
TE Code
AB
On Market Since
7/8/2013
Pharmacological Classes
Price Statistics
The NADAC for CEVIMELINE HCL 30 MG CAPSULE has been published 671 times since Nov 28, 2013, and over the history we have for it it has declined 66.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.7289 per EA |
|---|---|
| All-time high | $2.2833 (Jan 15, 2014) |
| All-time low | $0.6268 (Nov 20, 2024) |
| 52-week high | $0.7289 |
| 52-week low | $0.6572 |
| Median price | $1.1382 |
| Average price | $1.2740 |
| Largest weekly change | +42.0% (Aug 17, 2022) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Hikma Pharmaceuticals USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Cevimeline Hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Cholinergic Receptor Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CEVIMELINE HCL 30 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for CEVIMELINE HCL 30 MG CAPSULE, manufactured by Hikma Pharmaceuticals USA Inc., is $0.7289 per EA (NDC 00054033425), effective Sep 30, 2026.
How has the price of CEVIMELINE HCL 30 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for CEVIMELINE HCL 30 MG CAPSULE has declined 66.2%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for CEVIMELINE HCL 30 MG CAPSULE?
Since Nov 28, 2013, the NADAC for CEVIMELINE HCL 30 MG CAPSULE has ranged from a low of $0.6268 (Nov 20, 2024) to a high of $2.2833 (Jan 15, 2014), with a median of $1.1382 per EA.
Are there cheaper alternatives to CEVIMELINE HCL 30 MG CAPSULE?
2 manufacturers publish a NADAC-priced product with the same active ingredient and strength as CEVIMELINE HCL 30 MG CAPSULE in a comparable dosage form, but none are currently priced below it.
Who manufactures CEVIMELINE HCL 30 MG CAPSULE?
CEVIMELINE HCL 30 MG CAPSULE (NDC 00054033425) is labeled by Hikma Pharmaceuticals USA Inc., and CMS classifies it as a generic product.